Skip to main content
SpringerLink
Log in

Konsequenzen für die Praxis

Nationale VersorgungsLeitlinie „Therapie des Typ-2-Diabetes“

  • FORTBILDUNG_SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die Nationale VersorgungsLeitlinie „Therapie des Typ-2-Diabetes“ ist das Ergebnis eines langjährigen gemeinsamen Ringens um die bestmögliche Versorgungsstrategie für Typ-2-Diabetiker. Es ist ein großer Erfolg in der klinischen Diabetologie, dass erstmals im Rahmen dieser patientenorientierten integrativen Versorgungsstrategie in den wichtigsten Aspekten und Bereichen Einigung erzielt werden konnte.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Nationale VersorgungsLeitlinien. Therapie des Typ-2-Diabetes. http://www.diabetes.versorgungsleitlinien.de

  2. Kellerer M, Matthaei S (Hrsg.). Typ-2-Diabetes. Update 2013. als Pocket Guideline 2013, Börm Bruckmeier Verlag, München

  3. Landgraf R, Kellerer M, Fach E, Gallwitz B, Hamann A, Joost HG, Klein HH, Müller-Wieland D, Nauck MA, Reuter HM, Schreiber S, Siegel E, Matthaei S. Praxisempfehlungen DDG/DGIM - Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 2013;8 (Suppl 2):S135–S147

    Google Scholar 

  4. Abholz HH, Egidi G, Gries A, Haller N, Landgraf R, Loskill H, Matthaei St, Müller UA, Spranger J, Suchowerskyj A, Toeller M; Beteiligte: Khan C, Greiner F, Weikert B, Weinbrenner S, Kopp I, Ollenschläger G. Nationale VersorgungsLeitlinie „Therapie des Typ-2-Diabetes“. Deutsches Ärzteblatt 2013;110:A1875–1878

    Google Scholar 

  5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364–79

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes based on patient characteristics: What we know and what we need to know. J Clin Endocrinol Metab. 2010 Apr;95(4):1566–74

    Article  PubMed  CAS  Google Scholar 

  7. Gale EA. Is type 2 diabetes a category error? Lancet. 2013; 381:1956–7

    Article  PubMed  Google Scholar 

  8. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Landgraf R, Kowall B, Rathmann W. HbA1c - der Alleskönner? Therapiekontrolle, Screening und Diagnose des Diabetes. Diabetologe 2011;7:335–346

    Article  Google Scholar 

  10. Home PD. Validity of meta-analysis in diabetes: we need to be aware of its limitations. Diabetes Care. 2013 Oct;36(10):3361–7

    Article  PubMed  CAS  Google Scholar 

  11. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE’ comprehensice diabetes management algorithm 2013. Consensus statement. Endocrine Pract 2013; 19 (Suppl 2):1–48

    Article  Google Scholar 

  12. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010 Oct 7;363(15):1410–8.

    Article  PubMed  CAS  Google Scholar 

  13. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Lamina C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials Diabetes Obes and Metab 2011;13: 221–228

    Article  Google Scholar 

  15. Holstein A, Patzer OM, Machalke K, Holstein JD, Stumvoll M, Kovacs P. Substantial increase in incidence of severe hypoglycemia between 1997-2000 and 2007-2010: a German longitudinal population-based study. Diabetes Care. 2012 May;35(5):972–5

    Article  PubMed Central  PubMed  Google Scholar 

  16. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009 Dec 3;339:b4731

    Article  PubMed Central  PubMed  Google Scholar 

  17. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011 Aug;32(15):1900–8

    Article  PubMed  CAS  Google Scholar 

  18. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013 Oct;15(10):938–53

    Article  PubMed  CAS  Google Scholar 

  19. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013 Oct;30(10):1160–71

    PubMed  CAS  Google Scholar 

  20. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013 Apr 30;4:CD009008.

Download references

Author information

Authors and Affiliations

  1. Deutsche Diabetes-Stiftung (DDS), Staffelseestraße 6, D-81477, München, Deutschland

    Rüdiger Landgraf (Internist — Endokrinologe — Diabetologe, Vorsitzender)

Authors
  1. Rüdiger Landgraf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rüdiger Landgraf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landgraf, R. Konsequenzen für die Praxis. MMW - Fortschritte der Medizin 156, 76–79 (2014). https://doi.org/10.1007/s15006-014-2811-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-014-2811-6

Keywords - National practice guideline therapy of type 2 diabetes

Search

Navigation